These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7922004)

  • 1. CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
    Hale G; Waldmann H
    J Hematother; 1994; 3(1):15-31. PubMed ID: 7922004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
    Cobbold SP; Hale G; Clark MR; Waldmann H
    Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E; Or R; Nagler A; Cividalli G; Engelhard D; Aker M; Gimon Z; Manny N; Sacks T; Tochner Z
    Br J Haematol; 1995 Mar; 89(3):506-15. PubMed ID: 7734348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
    Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
    Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1996 Mar; 17(3):305-8. PubMed ID: 8704678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
    Willemze R; Richel DJ; Falkenburg JH; Hale G; Waldmann H; Zwaan FE; Fibbe WE
    Bone Marrow Transplant; 1992 Apr; 9(4):255-61. PubMed ID: 1600413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity.
    Condiotti R; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect.
    Novitzky N; Thomas V; Hale G; Waldmann H
    Transplantation; 1999 Feb; 67(4):620-6. PubMed ID: 10071037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
    Jacobs P; Wood L; Fullard L; Waldmann H; Hale G
    Bone Marrow Transplant; 1994 Jun; 13(6):763-9. PubMed ID: 7920312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.